Different weight loss strategies and their impact on fat and muscle tissue
https://doi.org/10.14341/DM13372
Abstract
The prevalence of obesity and its associated diseases continues to grow steadily worldwide, despite significant improvements in various treatment approaches. The advent of GLP-1 and GIP agonists and the development of bariatric surgery have significantly improved obesity treatment options, complementing dietary interventions, physical exercise, and a number of drugs that have long been used in clinical practice. At the same time weight loss strategies differ in their effects on fat and muscle tissue. It is well known that subcutaneous (SAT) and visceral (VAT) adipose tissues make unequal contributions to metabolic disorders in obesity, and reducing visceral adipose tissue is the most important goal during weight loss. Maintaining metabolically active muscle tissue and prevention of sarcopenia is also a very important issue. The question of different obesity treatment strategies impact on adipose and muscle tissue has attracted interest among researchers and clinicians, and therefore we have considered it in this review.
About the Authors
A. A. Voznesenskaya
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Anastasia A. Voznesenskaya - MD, PhD student.
11 Dm. Ulyanova street, 117292 Moscow
Competing Interests:
none
E. E. Rozhevskaya
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina E. Rozhevskaya - clinical resident.
Moscow
Competing Interests:
none
M. V. Shestakova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Marina V. Shestakova - MD, PhD, Professor, Academician of the RAS.
Moscow
Competing Interests:
none
References
1. World Obesity Federation. World Obesity Atlas 2024. London: World Obesity Federation, 2024. Available from: https://data.worldobesity.org/publications/?cat=22
2. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11-18. doi: https://doi.org/10.1111/j.1467-789X.2009.00623.x
3. Oliver CJ, Climstein M, Rosic N, Bosy-Westphal A, Tinsley G, Myers S. Fat-Free Mass: Friend or Foe to Metabolic Health?. J Cachexia Sarcopenia Muscle. 2025;16(1):e13714. doi: https://doi.org/10.1002/jcsm.13714
4. Johnson VR, Washington TB, Chhabria S, et al. Food as Medicine for Obesity Treatment and Management. Clin Ther. 2022;44(5):671-681. doi: https://doi.org/10.1016/j.clinthera.2022.05.001
5. McCarthy D, Berg A. Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients. 2021;13(7):2473. doi: https://doi.org/10.3390/nu13072473
6. Smith ES, Smith HA, Betts JA, et al. A Systematic Review and Meta-Analysis Comparing Heterogeneity in Body Mass Responses Between Low-Carbohydrate and Low-Fat Diets. Obesity (Silver Spring). 2020;28(10):1833-1842. doi: https://doi.org/10.1002/oby.22968
7. Tobias DK, Chen M, Manson JE, et al. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):968-979. doi: https://doi.org/10.1016/S2213-8587(15)00367-8
8. Goss AM, Gower B, Soleymani T, et al. Effects of weight loss during a very low carbohydrate diet on specific adipose tissue depots and insulin sensitivity in older adults with obesity: a randomized clinical trial. Nutr Metab (Lond). 2020;17:64. doi: https://doi.org/10.1186/s12986-020-00481-9
9. Garr Barry V, Stewart M, Soleymani T, et al. Greater Loss of Central Adiposity from Low-Carbohydrate versus Low-Fat Diet in Middle-Aged Adults with Overweight and Obesity. Nutrients. 2021;13(2):475. doi: https://doi.org/10.3390/nu13020475
10. Veum VL, Laupsa-Borge J, Eng Ø, et al. Visceral adiposity and metabolic syndrome after very high-fat and low-fat isocaloric diets: a randomized controlled trial. Am J Clin Nutr. 2017;105(1):85-99. doi: https://doi.org/10.3945/ajcn.115.123463
11. Meckling KA, O’Sullivan C, Saari D. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. J Clin Endocrinol Metab. 2004;89(6):2717-2723. doi: https://doi.org/10.1210/jc.2003-031606
12. Apekey TA, Maynard MJ, Kittana M, Kunutsor SK. Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2022;14(20):4391. doi: https://doi.org/10.3390/nu14204391
13. Waters DL, Aguirre L, Gurney B, et al. Effect of Aerobic or Resistance Exercise, or Both, on Intermuscular and Visceral Fat and Physical and Metabolic Function in Older Adults With Obesity While Dieting. J Gerontol A Biol Sci Med Sci. 2022;77(1):131-139. doi: https://doi.org/10.1093/gerona/glab111
14. O’Donoghue G, Blake C, Cunningham C, et al. What exercise prescription is optimal to improve body composition and cardiorespiratory fitness in adults living with obesity? A network meta-analysis. Obes Rev. 2021;22(2):e13137. doi: https://doi.org/10.1111/obr.13137
15. Yarizadeh H, Eftekhar R, Anjom-Shoae J, Speakman JR, Djafarian K. The Effect of Aerobic and Resistance Training and Combined Exercise Modalities on Subcutaneous Abdominal Fat: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Adv Nutr. 2021;12(1):179-196. doi: https://doi.org/10.1093/advances/nmaa090
16. Sabag A, Way KL, Keating SE, et al. Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2017;43(3):195-210. doi: https://doi.org/10.1016/j.diabet.2016.12.006
17. An J, Su Z, Meng S. Effect of aerobic training versus resistance training for improving cardiorespiratory fitness and body composition in middle-aged to older adults: A systematic review and meta-analysis of randomized controlled trials. Arch Gerontol Geriatr. 2024;126:105530. doi: https://doi.org/10.1016/j.archger.2024.105530
18. Bellicha A, van Baak MA, Battista F, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. Obes Rev. 2021;22(Suppl 4):e13256. doi: https://doi.org/10.1111/obr.13256
19. Dedov II, Melnichenko GA, Troshina EA, Mazurina NV, Galieva MO. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11(4):335-343. doi: https://doi.org/10.1159/000488880
20. Ametov AS. Effective treatment of obesity: ways to fight epidemic of diabetes mellitus. Meditsinskiy sovet = Medical Council. 2013;(2-2):78-83. (In Russ.) doi: https://doi.org/10.21518/2079-701X-2013-2-2-78-83
21. Hauner H, Meier M, Wendland G, et al. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes. 2004;112(4):201-207. doi: https://doi.org/10.1055/s-2004-817934
22. Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology. 2008;135(4):1142-54. doi: https://doi.org/10.1053/j.gastro.2008.07.009
23. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?. Int J Obes Relat Metab Disord. 1998;22 Suppl 1:S38-S42
24. Porter JA, Raebel MA, Conner DA, et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004;10(6):369-376
25. Российская ассоциация эндокринологов. Клинические рекомендации. Ожирение, взрослые. — M.: МЗ РФ; 2024 [Rossijskaja associacija endokrinologov. Klinicheskie rekomendacii. Ozhirenie, vzroslye. Moscow: MZ RF; 2024. (In Russ.)
26. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. doi: https://doi.org/10.2337/diacare.27.1.155
27. Smith SR, Stenlof KS, Greenway FL, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring). 2011;19(9):1796-1803. doi: https://doi.org/10.1038/oby.2011.143
28. Shirai K, Tanaka M, Fujita T, et al. Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study. Adv Ther. 2019;36(1):217-231. doi: https://doi.org/10.1007/s12325-018-0822-x
29. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord. 2000;24(12):1567-1572. doi: https://doi.org/10.1038/sj.ijo.0801443
30. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873-2883. doi: https://doi.org/10.1001/jama.293.23.2873
31. Pillai AA, Melo L, Frishman WH, Aronow WS. The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity. Cardiol Rev. doi: https://doi.org/10.1097/CRD.0000000000000832
32. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170(10):682-690. doi: https://doi.org/10.7326/M18-1605
33. Pu R, Shi D, Gan T, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020;11:2042018820926000. doi: https://doi.org/10.1177/2042018820926000
34. Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Obesity and metabolism. 2009;6(2):50-51. (In Russ.) doi: https://doi.org/10.14341/2071-8713-5321
35. Sokolova AV, Klimova AV, Dragunov DO, Arutyunov GP. Effect of metformin therapy on muscle mass and strength in patients with and without diabetes. Meta-analysis of 15 studies. Russ J Cardiol. 2021;26(3):4331. (In Russ.) doi: https://doi.org/10.15829/1560-4071-2021-4331
36. Wang H, Ni Y, Yang S, et al. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp. 2013;75:88-92. doi: https://doi.org/10.1016/j.curtheres.2013.10.002
37. van der Aa MP, Elst MA, van de Garde EM, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6(8):e228. doi: https://doi.org/10.1038/nutd.2016.37
38. Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diabetes Investig. 2019;10(2):399-407. doi: https://doi.org/10.1111/jdi.12888
39. Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34(11):2381-2386. doi: https://doi.org/10.2337/dc11-1032
40. Rodríguez-Moctezuma JR, Robles-López G, López-Carmona JM, Gutiérrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab. 2005;7(2):189-192. doi: https://doi.org/10.1111/j.1463-1326.2004.00385.x
41. Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019;79(3):219-230. doi: https://doi.org/10.1007/s40265-019-1057-0
42. Ohkuma T, Van Gaal L, Shaw W, et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes Obes Metab. 2020;22(4):530-539. doi: https://doi.org/10.1111/dom.13920
43. Heymsfield SB, Raji A, Gallo S, et al. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus. Obesity (Silver Spring). 2020;28(4):724-732. doi: https://doi.org/10.1002/oby.22748
44. Antsiferov MB, Demidov NA. Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow). Diabetes Mellitus. 2025;28(1):80-90. (In Russ.) doi: https://doi.org/10.14341/DM13262
45. Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes. Intern Med. 2017;56(6):597-604. doi: https://doi.org/10.2169/internalmedicine.56.7196
46. Liu X, Chen Y, Liu T, et al. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1115321. doi: https://doi.org/10.3389/fendo.2023.1115321
47. Post A, Groothof D, Eisenga MF, Bakker SJL. Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?. J Clin Med. 2020;9(5):1603. doi: https://doi.org/10.3390/jcm9051603
48. Tucker ME. Womens weight gain higher on thiazolidinedione. Fam Pract News. 2005;35(13):22. doi: https://doi.org/10.1016/s0300-7073(05)70935-x
49. Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2020;8(7):616-627. doi: https://doi.org/10.1016/S2213-8587(20)30110-8
50. Yokota T, Kinugawa S, Hirabayashi K, et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J Diabetes Investig. 2017;8(4):535-541. doi: https://doi.org/10.1111/jdi.12606
51. Bastien M, Poirier P, Brassard P, et al. Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: a 1-yr randomized study. Am J Physiol Endocrinol Metab. 2019;317(1):E65-E73. doi: https://doi.org/10.1152/ajpendo.00505.2018
52. Massimino E, Izzo A, Riccardi G, Della Pepa G. The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells. 2021;10(8):1958. doi: https://doi.org/10.3390/cells10081958
53. Phua WWT, Wong MXY, Liao Z, Tan NS. An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors. Int J Mol Sci. 2018;19(5):1425. doi: https://doi.org/10.3390/ijms19051425
54. Gavrilova AO, Shestakova EA, Shestakova MV, et al. Sravnenie sakharosnizhayushchego effekta i vliyaniya na massu tela semaglutida 1,0 mg i liraglutida 3,0 mg u patsientov s ozhireniem i sakharnym diabetom 2 tipa // Fundamental’naya i klinicheskaya diabetologiya v 21 veke: ot teorii k praktike : Sbornik tezisov III Konferentsii po lecheniyu i diagnostike sakharnogo diabeta, Moskva, 25–26 maya 2023 goda. – Moskva: Obshchestvo s ogranichennoi otvetstvennost’yu «Tipografiya «Pechatnykh Del Master», 2023. (In Russ.) doi: https://doi.org/10.14341/DIAConfIII25-26.05.23-30
55. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: https://doi.org/10.1056/NEJMoa1411892
56. Neeland IJ, Marso SP, Ayers CR, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595-605. doi: https://doi.org/10.1016/S2213-8587(21)00179-0
57. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843-854. doi: https://doi.org/10.1038/ijo.2011.158
58. Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215-218. doi: https://doi.org/10.1111/dom.13053
59. Tomilova AO. Dinamika gormonal’no-metabolicheskih faktorov i vospalitel’nogo potenciala zhirovoj tkani na fone medikamentoznogo i hirurgicheskogo metodov lecheniya lic s ozhireniem i saharnym diabetom 2 tipa. [dissertation] Moscow; 2025. (In Russ.) Доступно по: http://endocrincentr.ru/specialists/science/dissertacionnyy-sovet/dissertacii/dinamika-gormonalno-metabolicheskih-faktorov-i-vospalitelnogo-potenciala Ссылка активна на 06.04.2025
60. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023;25(1):18-35. doi: https://doi.org/10.1111/dom.14863
61. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17. doi: https://doi.org/10.1210/jendso/bvab048.030
62. Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206. doi: https://doi.org/10.1016/S2213-8587(22)00008-0
63. Nelson LW, Lee MH, Garrett JW, et al. Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy. AJR Am J Roentgenol. 2024;223(6):e2431805. doi: https://doi.org/10.2214/AJR.24.31805
64. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi: https://doi.org/10.1111/dom.16275
65. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406. doi: https://doi.org/10.1016/S2213-8587(22)00070-5
66. Cariou B, Linge J, Neeland IJ, et al. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes Obes Metab. 2024;26(6):2446-2455. doi: https://doi.org/10.1111/dom.15566
67. Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014. Obes Surg. 2017;27(9):2279-2289. doi: https://doi.org/10.1007/s11695-017-2666-x
68. Tałałaj M, Bogołowska-Stieblich A, Wąsowski M, et al. The Influence of Laparoscopic Sleeve Gastrectomy on Body Composition and Fat Distribution in Obese Caucasian Men and Women. Obes Surg. 2020;30(10):3974-3981. doi: https://doi.org/10.1007/s11695-020-04766-z
69. Haghighat N, Kazemi A, Asbaghi O, et al. Long-term effect of bariatric surgery on body composition in patients with morbid obesity: A systematic review and meta-analysis. Clin Nutr. 2021;40(4):1755-1766. doi: https://doi.org/10.1016/j.clnu.2020.10.001
70. Ito MK, Gonçalves VSS, Faria SLCM, et al. Effect of Protein Intake on the Protein Status and Lean Mass of Post-Bariatric Surgery Patients: a Systematic Review. Obes Surg. 2017;27(2):502-512. doi: https://doi.org/10.1007/s11695-016-2453-0
71. Jassil FC, Papageorgiou M, Mackay E, et al. One Year Changes in Body Composition and Musculoskeletal Health Following Metabolic/Bariatric Surgery. J Clin Endocrinol Metab. 2025;110(5):e1598-e1608. doi: https://doi.org/10.1210/clinem/dgae496
72. Kenngott HG, Nickel F, Wise PA, et al. Weight Loss and Changes in Adipose Tissue and Skeletal Muscle Volume after Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: a Prospective Study with 12-Month Follow-Up. Obes Surg. 2019;29(12):4018-4028. doi: https://doi.org/10.1007/s11695-019-04087-w
73. Yashkov YI, Bordan NS, Malykhina AI, Bekuzarov DK. A comparative evaluation of five-year results of SADI-S and biliopancreatic diversion/Duodenal Switch (Hess-Marceau). Moscow Surgical Journal. 2020;(1):111-119. (In Russ.) doi: https://doi.org/10.17238/issn2072-3180.2020.1.111-119
74. Zhang Z, Wang L, Wei Z, Zhang Z, Cui L, Jiang T. Analysis of the 1-year efficacy of four different surgical methods for treating Chinese super obese (BMI ≥ 50 kg/m2) patients. Sci Rep. 2024;14(1):10451. doi: https://doi.org/10.1038/s41598-024-60983-x
75. Auclair A, Piché ME, Biertho L, et al. Changes in fat-free mass and muscle mass at 6 and 12 months after biliopancreatic diversion with duodenal switch surgery. Surg Obes Relat Dis. 2020;16(7):878-885. doi: https://doi.org/10.1016/j.soard.2020.03.012
76. Shestakova E, Stafeev I, Yashkov Y, et al. Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery. J Clin Med. 2024;13(22):6998. doi: https://doi.org/10.3390/jcm13226998
77. Nuijten MAH, Eijsvogels TMH, Monpellier VM, et al. The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2022;23(1):e13370. doi: https://doi.org/10.1111/obr.13370
78. Fischer L, Hildebrandt C, Bruckner T, et al. Excessive weight loss after sleeve gastrectomy: a systematic review. Obes Surg. 2012;22(5):721-731. doi: https://doi.org/10.1007/s11695-012-0616-1
79. O’Brien PE, Hindle A, Brennan L, et al. Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding. Obes Surg. 2019;29(1):3-14. doi: https://doi.org/10.1007/s11695-018-3525-0Сахарный диабет. 2026;29(2):203-214
Supplementary files
|
|
1. Figure 1. Effects of different pharmacological approaches on body weight and visceral adipose tissue. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(529KB)
|
Indexing metadata ▾ | |
Review
For citations:
Voznesenskaya A.A., Rozhevskaya E.E., Shestakova M.V. Different weight loss strategies and their impact on fat and muscle tissue. Diabetes mellitus. 2026;29(2):203-214. (In Russ.) https://doi.org/10.14341/DM13372
Views:
384
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
